Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder
CHESTERBROOK, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced …